SCPS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.10%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Scopus BioPharma Insider Trading History Chart

Scopus BioPharma Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 04/26/2024 10:30 AM ET

Days: 30 | 90 | 365

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

From Paradigm Press | Ad

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Scopus BioPharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/26/2021	Joshua R. Lamstein	Chairman	Buy	200	$4.90	$980.00
8/23/2021	Ira Scott Greenspan	Chairman	Buy	500	$4.41	$2,205.00
8/19/2021	Ira Scott Greenspan	Chairman	Buy	2,000	$4.04	$8,080.00	81,790
8/17/2021	Ira Scott Greenspan	Chairman	Buy	1,000	$4.13	$4,130.00
7/26/2021	Ira Scott Greenspan	Chairman	Buy	400	$4.76	$1,904.00
7/23/2021	Ira Scott Greenspan	Chairman	Buy	1,100	$4.77	$5,247.00	118,797

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

SEC Filings (Institutional Ownership Changes) for Scopus BioPharma (NASDAQ:SCPS)

Institutional Buying and Selling by Quarter

Scopus BioPharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/4/2022	M&R Capital Management Inc.	76,819	$53K	0.0%	N/A	0.425%
11/15/2021	First Manhattan Co.	27,800	$0.12M	0.0%	+198.9%	0.154%
11/9/2021	BlackRock Inc.	19,018	$79K	0.0%	+1,399.8%	0.105%
8/12/2021	JPMorgan Chase & Co.	9,338	$67K	0.0%	-54.5%	0.059%
8/12/2021	Ergoteles LLC	23,450	$0.17M	0.0%	N/A	0.149%
5/18/2021	Millennium Management LLC	92,104	$0.78M	0.0%	N/A	0.000%
5/18/2021	California State Teachers Retirement System	8,365	$71K	0.0%	N/A	0.000%
5/17/2021	Royal Bank of Canada	3,592	$30K	0.0%	N/A	0.000%
5/12/2021	Northern Trust Corp	47,633	$0.40M	0.0%	N/A	0.000%
5/12/2021	Geode Capital Management LLC	52,159	$0.44M	0.0%	N/A	0.000%
5/12/2021	JPMorgan Chase & Co.	20,527	$0.17M	0.0%	N/A	0.000%
5/11/2021	New York State Common Retirement Fund	8,705	$74K	0.0%	N/A	0.000%
5/7/2021	BlackRock Inc.	108,237	$0.92M	0.0%	N/A	0.000%
5/7/2021	American International Group Inc.	3,232	$27K	0.0%	N/A	0.000%
2/24/2021	Virtu Financial LLC	16,280	$0.24M	0.0%	N/A	0.000%

Data available starting January 2016

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.